Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

AIMS: SYNERGY II was a 12‐month phase III trial in patients with overactive bladder (OAB) symptoms that investigated the safety and efficacy of the combination of mirabegron and solifenacin in comparison with each monotherapy. This analysis evaluated the trial findings using four age subgroups (<...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Elizabeth R., van Maanen, Rob, Chapple, Christopher, Abrams, Paul, Herschorn, Sender, Robinson, Dudley, Stoelzel, Matthias, Yoon, Sang J., Al‐Shukri, Salman, Rechberger, Tomasz, Gratzke, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850571/
https://www.ncbi.nlm.nih.gov/pubmed/30644570
http://dx.doi.org/10.1002/nau.23919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850571/
https://www.ncbi.nlm.nih.gov/pubmed/30644570
http://dx.doi.org/10.1002/nau.23919

Ejemplares similares